Drug intelligence / Profile preview

OC202e

Development stage: Preclinical
Lead developer: Oncocross
Modality: Small Molecules

Overview

OC202e is an AI-driven therapeutic candidate developed by Oncocross Co., Ltd. for the treatment of pancreatic cancer. It is designed to enhance the efficacy of standard chemotherapy regimens, such as FOLFIRINOX, by modulating the hypoxia-inducible factor 1-alpha (HIF-1α) and the epithelial-mesenchymal transition (EMT)-stemness axis. By targeting these pathways, OC202e aims to suppress tumor metastasis and overcome multidrug resistance. Preclinical studies have demonstrated that OC202e, particularly when used in combination with OC201, reduces the expression of stemness markers like CD44 and Flotillin-2, thereby decreasing clonogenic potential and metastatic burden in pancreatic cancer models.

Targets

HIF1A (Hypoxia-inducible factor 1-alpha)CD44 (CD44 antigen)FLOT2 (Flotillin-2)

Beyond the preview

Go deeper on OC202e.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OC202e.

Explore the full profile